Home > Insider Trading > Filing (0001445064-15-000090)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1567892	Mallinckrodt Plc	MNK	Pharmaceutical Preparations (2834)	981088325

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1223697	M Don Bailey	675 Mcdonnell Blvd. Hazelwood MO 63042		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2015-05-13	51,417	$26.95	191,024	No	4	M	Direct
Ordinary Shares	Disposition	2015-05-13	50,017	$122.43	141,007	No	4	S	Direct
Ordinary Shares	Disposition	2015-05-13	1,400	$123.18	139,607	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Options (Right to Buy)	Disposition	2015-05-13	51,417	$0.00	51,417	$26.95

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2022-02-15	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on November 26, 2014.
The price represents a weighted average. The shares were sold at prices ranging from $122.02 to $123.00, inclusive. Mr. Bailey will provide, upon request of the SEC staff, Mallinckrodt plc, or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) - (3) to this Form 4.
The price represents a weighted average. The shares were sold at prices ranging from $123.12 to $123.50, inclusive.
Represents options to purchase shares of Questcor Pharmaceuticals, Inc. that were converted into options to purchase ordinary shares of Mallinckrodt plc pursuant to the Agreement and Plan of Merger, dated as of April 5, 2014, by and among Mallinckrodt plc ("Mallinckrodt"), Questcor Pharmaceuticals, Inc. ("Questcor") and Quincy Merger Sub, Inc. All unvested options were accelerated on August 14, 2014 in connection with the acquisition of Questcor by Mallinckrodt.